GB0226595D0 - Cancer therapy determination - Google Patents

Cancer therapy determination

Info

Publication number
GB0226595D0
GB0226595D0 GBGB0226595.7A GB0226595A GB0226595D0 GB 0226595 D0 GB0226595 D0 GB 0226595D0 GB 0226595 A GB0226595 A GB 0226595A GB 0226595 D0 GB0226595 D0 GB 0226595D0
Authority
GB
United Kingdom
Prior art keywords
cancer therapy
therapy determination
determination
cancer
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0226595.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University of Belfast
Original Assignee
Queens University of Belfast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queens University of Belfast filed Critical Queens University of Belfast
Priority to GBGB0226595.7A priority Critical patent/GB0226595D0/en
Publication of GB0226595D0 publication Critical patent/GB0226595D0/en
Priority to AU2003283339A priority patent/AU2003283339A1/en
Priority to PCT/EP2003/012245 priority patent/WO2004042080A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
GBGB0226595.7A 2002-11-05 2002-11-15 Cancer therapy determination Ceased GB0226595D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0226595.7A GB0226595D0 (en) 2002-11-15 2002-11-15 Cancer therapy determination
AU2003283339A AU2003283339A1 (en) 2002-11-05 2003-11-03 Cancer therapy determination
PCT/EP2003/012245 WO2004042080A1 (en) 2002-11-05 2003-11-03 Cancer therapy determination

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0226595.7A GB0226595D0 (en) 2002-11-15 2002-11-15 Cancer therapy determination

Publications (1)

Publication Number Publication Date
GB0226595D0 true GB0226595D0 (en) 2002-12-24

Family

ID=9947830

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0226595.7A Ceased GB0226595D0 (en) 2002-11-05 2002-11-15 Cancer therapy determination

Country Status (3)

Country Link
AU (1) AU2003283339A1 (en)
GB (1) GB0226595D0 (en)
WO (1) WO2004042080A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL217731B1 (en) * 2006-06-01 2014-08-29 Tomasz Byrski Detection of lowered response for chemotherapy with the use of cytostatics from a group of toxoids
PL212012B1 (en) * 2008-07-06 2012-07-31 Tomasz Byrski Detection of existence of increased risk of chemotherapy side effects by the use of platinum cytostatics
US8110185B2 (en) 2008-10-03 2012-02-07 St. Michael's Hospital Method for preventing and treating cardiovascular diseases with BRCA1
AU2011293635B2 (en) 2010-08-24 2015-11-26 Children's Medical Center Corporation Methods for predicting anti-cancer response
NZ628813A (en) 2012-02-23 2015-10-30 Univ Denmark Tech Dtu Methods for predicting anti-cancer response
GB2553736A (en) * 2015-05-19 2018-03-14 S Sridhar T Method for identification of a deficient BRCA1 function

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2473642A1 (en) * 2002-01-25 2003-08-07 Sheikh Ismail Electrophoretic assay to predict risk of cancer and the efficacy and toxicity of cancer therapy

Also Published As

Publication number Publication date
WO2004042080A1 (en) 2004-05-21
AU2003283339A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
EP1482970A4 (en) Cancer therapy
IL251270A0 (en) Cancer treatment
EP1535610A4 (en) Therapeutic agent for cancer
IL164599A0 (en) Combination therapy for the treatment of cancer
EP1572131A4 (en) Antibody therapy
AU2003235470A8 (en) Predictive markers in cancer therapy
HK1082378A1 (en) Cancer therapy sensitizer
EP1581244A4 (en) Novel therapeutic targets in cancer
GB0218526D0 (en) Combination therapy
EP1401494A4 (en) Tumor therapy
GB0226595D0 (en) Cancer therapy determination
AU2003231803A8 (en) Treatment of cancer with mefloquire
GB0223325D0 (en) Treating cancer
EP1463511A4 (en) Combination cancer therapy
GB2383538B (en) Cancer treatment
GB0303289D0 (en) Combination therapy
GB0213474D0 (en) Tumour therapy
AU2003238722A8 (en) Cancer therapy by modulating cdc42-activity
GB0218725D0 (en) Cancer related methods
GB0207031D0 (en) Treating cancer
GB0220841D0 (en) Therapy
GB0230027D0 (en) Therapy
GB0208680D0 (en) Combination therapy
GB0212396D0 (en) Combination therapy
GB0218388D0 (en) Combination therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)